WooGene B&G Co (018620) Fair Value & Analysis
Healthcare · KR · Market cap 17.4B KRW
Fair value as of: Jul 20, 2026
From 13 valuation models · updated 21 days ago
Share price −16.8% over the past month.
Below-average quality, and screening another 59% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,618 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (707.46 KRW to 1,618 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 2,245 KRW – 13,708 KRW · fair‑value band 707.46 KRW – 1,618 KRW · the 2,550 KRW price screens above the 1,050 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
WooGene B&G Co (018620) currently trades at 2,550 KRW, while our model-based Fair Value estimate is 1,050 KRW, implying the stock looks roughly 58.8% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, WooGene B&G Co generated revenue of 47.6B KRW at a net margin of -2.8%. Revenue grew 16.0% year over year. Net debt stands at 16.8B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 707.46 KRW (bear case) to 1,618 KRW (bull case); at 2,550 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -59%, 018620 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: DCF Models (1,019 KRW) versus Earnings-Based (273.42 KRW). Highest evidence: Growth DCF (80).
Notify me when 018620 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic.
Full company description
WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
WooGene B&G Co reported revenue of 54.8B KRW in FY2025 versus 39.3B KRW in FY2021, a compound +8.6%/yr. Reported net income was −1.8B KRW in FY2025.
018620 screens 59% overvalued. Compare with GlaxoSmithKline Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceuticals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,653 | ₹1,471 | -45% |
| Caregen Co 214370 | 62,700 KRW | 7,277 KRW | -88% |
| ST Pharm Co 237690 | 123,600 KRW | 50,110 KRW | -59% |
| Oscotec Inc 039200 | 31,050 KRW | 25,062 KRW | -19% |
| DongKook Pharmaceutical Co 086450 | 18,350 KRW | 32,142 KRW | +75% |
| Kolon Life Science Inc 102940 | 30,100 KRW | 37,195 KRW | +24% |
| Huons Global Co 084110 | 23,800 KRW | 58,482 KRW | +146% |
| BINEX Co 053030 | 6,350 KRW | 1,844 KRW | -71% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 16,810 KRW | 4,741 KRW | -72% |
| EURO EURO | 1.09 PHP | 0.8700 PHP | -20% |
Compare WooGene B&G Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is WooGene B&G Co (018620) overvalued or undervalued?
What is the fair value of 018620?
What is the quality score of 018620?
What is the revenue of WooGene B&G Co (018620)?
What is the net profit margin of 018620?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track WooGene B&G Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.